Introduction {#Sec1}
============

Neuroendocrine carcinomas, particularly large-cell neuroendocrine carcinoma (LCNEC) of the ovary, are extremely rare but aggressive neoplasms. The other common subtypes of ovarian cancer such as high-grade serous, mucinous, or endometrioid carcinoma are often associated with LCNEC. LCNEC can follow a different clinical course with more adverse outcomes. Early and accurate diagnosis of LCNEC can be the best way to proceed to the optimal treatment and improve the prognosis of these patients. However, there are no optimal diagnostic and treatment strategies because of the paucity of evidence about the clinical or imaging features.

Currently, diagnostic laparoscopy has been used to determine the treatment strategy, including primary optimal cytoreductive surgery or neoadjuvant chemotherapy, in patients with advanced epithelial ovarian cancer, although the role of diagnostic laparoscopy is still unclear in LCNEC. A case of diagnostic laparoscopy with no perioperative complications resulting in the early start of postoperative chemotherapy is presented, along with a review of the literature to explain the role of diagnostic laparoscopy in selecting the optimal treatment for LCNEC patients.

Case presentation {#Sec2}
=================

A 31-year-old woman (gravida 0, para 0) visited the hospital due to abdominal distension. She had been in good health. Physical examination showed a markedly distended abdomen. Abdominal ultrasound (US) showed a pelvic mass and gross ascites. She was referred to our hospital for further examination and subsequent treatment.

Transvaginal US showed the presence of marked ascites and a large solid and cystic mass with a diameter of 20 cm around the uterus in the pelvic cavity. CT of the abdomen and pelvis showed gross ascites that extended under the diaphragm, a strongly enhanced, heterogeneous, huge mass in the pelvic cavity, and multiple peritoneal nodule lesions. There was no lymphadenopathy. On pelvic MRI, the pelvic mass showed homogeneous low intensity on T1-weighted MRI and heterogeneous low and high intensities on T2-weighted MRI, suggesting the presence of cystic and solid lesions. There were no fatty components. The patient's serum CA 125 level was 165.7 U/ml (normal value \< 35 U/ml). Serum CEA and CA 19--9 levels were within normal ranges. The pelvic cyst with solid components, the high CA 125 level, massive ascites, and multiple peritoneal nodule lesions strongly indicated the presence of an advanced ovarian cancer.

The patient underwent whole-body FDG PET/MRI to confirm malignancy and the presence of lymph node or distant metastases. The huge mass in the pelvic cavity and multiple peritoneal nodule lesions showed strong FDG uptake (Fig. [1](#Fig1){ref-type="fig"}a and b). She underwent abdominal paracentesis several times to confirm malignant cells in the ascitic fluid and reduce the abdominal discomfort caused by the massive ascites. However, cytological examinations showed only mesothelial cells without any malignant cells despite the imaging appearance of suspected malignancy on CT, MRI, and FDG-PET. Fig. 1Whole-body FDG PET shows strong FDG uptake in multiple peritoneal nodule lesions (**a**). Integrated FDG-PET/T2-weighted MRI shows strong FDG uptake in the huge mass in the pelvic cavity (arrows) (**b**). Laparoscopic findings show the huge mass with a diameter greater than 20 cm in the pelvic cavity and strongly adhered to the adjacent organs (arrows) (**c**) and the countless disseminated lesions of various sizes in the intraperitoneal organs (arrows) (**d**)

Therefore, exploratory laparoscopy was performed for diagnostic purposes, and 6900 ml of bloody serous ascites were evacuated and obtained for cytology. A huge mass with a diameter of more than 20 cm occupied the pelvic cavity and adhered strongly to adjacent organs including the uterus, adnexa, and rectum (Fig. [1](#Fig1){ref-type="fig"}c). It was decided that the optimal surgery could not be performed because there were countless disseminated lesions of various sizes in the intraperitoneal organs, including the omentum, mesentery, and peritoneum (Fig. [1](#Fig1){ref-type="fig"}d). Therefore, one nodule of the omentum was resected by a harmonic device for frozen section examination, and it was diagnosed as adenocarcinoma. Additional resection of the omental nodule was performed for permanent fixation and further pathological examination. The pathological examination showed that the tumor consisted of small cells and large cells with hyperchromatic nuclei and a high mitotic rate, showing nested, trabecular, and pseudoglandular growth patterns (Fig. [2](#Fig2){ref-type="fig"}a). There was no other histologic subtype. Immunohistochemical analysis showed that these cells were positive for neuroendocrine markers such as synaptophysin and CD56, and the Ki-67 index was greater than 20% (Fig. [2](#Fig2){ref-type="fig"}b, c and d). Cytological examination of the obtained ascitic fluid showed no malignant cells. There were no other suspicious malignant lesions in the lung or digestive system on CT or FDG-PET. Therefore, the final pathological diagnosis was large cell neuroendocrine carcinoma of the ovaries with FIGO stage IIIC. Fig. 2Hematoxylin and eosin-stained paraffin section of the tumor at × 40 magnification shows that the tumor consists of small cells and large cells with hyperchromatic nuclei and a high mitotic rate, with nested, trabecular, and pseudoglandular growth patterns (**a**). Immunohistochemical analysis at × 40 magnification shows that these cells are positive for the neuroendocrine markers, synaptophysin (**b**) and CD56 (**c**). The Ki-67 index is greater than 20% (**d**)

The patient's postoperative course was uneventful. On the 11th day after surgery, she received the first course of chemotherapy with etoposide and cisplatin. After 2 courses of the chemotherapy, the symptoms of abdominal distension had improved, although there was residual tumor in the abdominal cavity. However, the residual tumor then increased rapidly, and the patient died 2 months after surgery.

Discussion and conclusions {#Sec3}
==========================

Neuroendocrine carcinomas (NECs) are rare but aggressive types of neoplasms that are generally seen in the lungs or gastrointestinal tract, whereas they are very rarely seen at sites in the female genital tract including the ovaries. Family history of cancer, body mass index, diabetes mellitus, cigarette smoking and alcohol consumption have been reported as the potential risk factors for NECs of the pancreas, small intestine, and rectum, whereas the risk factors for NECs in the ovaries remain unknown \[[@CR1]\]. The 2014 WHO classification of ovarian tumors included carcinoid and small-cell carcinoma, pulmonary type, but no separate category of NEC. Moreover, large-cell NEC arises very rarely in the ovary, although the WHO classification does not include it \[[@CR2]\]. NECs account for only 0.1% of all ovarian cancers and are often associated with other epithelial carcinomas, such as high-grade serous, mucinous, or endometrioid carcinoma. Unlike carcinoid, small-cell and large-cell NECs of the ovaries often occur in young women, with a median age of 23.9 years, and are associated with a much poorer prognosis \[[@CR3]\]. Surgery with the aim of diagnosis and complete resection and adjuvant chemotherapy with platinum-based chemotherapy have been used regardless of the paucity of data. Pathological examination shows large cells with significant pleomorphism, large nuclei with coarse and granular chromatin, prominent nucleoli, significant mitotic activity, and palisading with rosette formation. Immunohistochemical analysis shows positivity for one or more of the neuroendocrine markers such as synaptophysin, CD56, or chromogranin in at least 10% of tumor cells. In many cases, the early and accurate diagnosis of NEC can be the best way to improve the prognosis of NEC of the ovaries.

The clinicopathological features of 31 cases with FIGO stage I/II (Table [1](#Tab1){ref-type="table"}) \[[@CR4]--[@CR24]\] and 25 cases with FIGO stage III/IV (Table [2](#Tab2){ref-type="table"}) \[[@CR7], [@CR8], [@CR14], [@CR17], [@CR18], [@CR20], [@CR25]--[@CR35]\] were reviewed. A Kaplan-Meier survival curve (SPSS Statistics version 24; IBM, Armonk, NY) of all 53 cases excluding 3 cases without clinical outcome data showed total 5-year survival of 34.6% and median survival time of 17 months. There were no significant differences between the cases with FIGO stage I/II (*n* = 28) and III/IV (*n* = 25), with total 5-year survival of 38.8 and 29.2% and median survival time of 19 and 9 months, respectively (*p* = 0.458). These results were almost similar to the previous report by Oshita et al. \[[@CR18]\], suggesting that cases with LCNEC showed much worse clinical outcomes than the other subtypes, such as epithelial ovarian cancer even in early disease, regardless of FIGO stage. In particular, cases with carcinomatous peritonitis (*n* = 11) showed significantly much poorer clinical outcomes than cases without carcinomatous peritonitis (*n* = 42), with median survival time of 7 and 20 months, respectively (*p* = 0.036), suggesting that a different therapeutic strategy should be considered in these cases (Fig. [3](#Fig3){ref-type="fig"}). Table 1Literature review of LCNEC of FIGO stage I and II or undecidedStudyAge (y)FIGO stageSize (cm)Associated componentMetastatic siteAscitic fluid cytologyTreatmentOutcomeCollins et al., 1991 \[[@CR4]\]34IC16Mucinous cystadenoma & mucinous adenoCaNoneN/A (bloody 4 l)TAH/BSO/OM + CDDP/CPADOD 8 monthsKhurana et al., 1994 \[[@CR5]\]22I21Mucinous cystadenoma & mucinous adenoCaNoneN/ARSO/AP + CBDCA + CPADOD 3 monthsJones et al., 1996 \[[@CR6]\]65IA16.5Mucinous cystadenomaNoneNegative (1.6 l)TAH/BSO/OM/PLN/APDOD 10 monthsEichhorn et al., 1996 \[[@CR7]\]77IA15Endometrioid adenoCa grade 1NoneN/ATAH/BSO/LN & peritoneal biopsiesDOD 19 months36IA10Mucinous adenoCaNoneN/ARSO/APRecent45IB18Mucinous borderline tumor with small foci of mucinous adenoCaNoneN/ATAH/BSO/OM + ChemDOD 36 months68IIB9Mucinous adenoCaRight tubeN/ATAH/RSO/OM/peritoneal biopsyLost to follow-upChen, 2000 \[[@CR8]\]44IA25Mucinous intraepithelial adenoCaNoneN/ATAH/BSO/OM + PTX + CBDCADOD 4 monthsBehnam et al., 2004 \[[@CR9]\]27IA17Pure LCNECNoneN/ALSO/right OV & pelvic wall biopsies/PAN//OM/AP + PTX + CBDCANED 10 monthsHirasawa, 2004 \[[@CR10]\]56IIC18Mucinous adenoCa & dermoid cystRectumPositive (adenoCa)TAH/BSO/rectal serosa resection/PLNDOD 10 months35ICN/AMucinous adenomaNoneN/ATAH/BSO/OM + CDDP (ip) + high-dose ChemNED 10 yearsOhira et al., 2004 \[[@CR11]\]33IC11Endometrioid adenoCa grade 1NoneRupturedLSO/right OV biopsy/OM + CPT-11/NedaplatinDOD 6 monthsAhmed et al., 2005 \[[@CR12]\]31N/A15Mucinous cystadenomaN/AN/AN/AN/ALindboe, 2007 \[[@CR13]\]64IA14Pure LCNECNoneNegativeTAH/BSO/OM + Bleomycin/CDDP/EtoposideNED 9 monthsVeras et al., 2007 \[[@CR14]\]55I26Mucinous low malignant potential with intraepithelial CaN/AN/ATAH/BSO + platinum-based ChemNED 68 months54I14Mucinous & endometrioid CaN/AN/ATAH/BSO + platinum-based ChemNED 66 months59I14High-grade adenoCa, not otherwise specifiedN/AN/ABSO + platinum-based ChemNED 28 months22I21Mucinous low malignant potential with mucinous CaN/AN/ARSO/AP + platinum-based ChemDOD 3 monthsTartaglia et al., 2008 \[[@CR15]\]56IIA8Pure LCNECEndometriumNegativeTAH/BSO/pelvic wall biopsies/OM/AP/PAN + PTX/CBDCANED 10 monthsAslam et al., 2009 \[[@CR16]\]76IIB30Pure LCNECDouglas pouchN/ATAH/BSO/OM/AP/PLN/PAN/Douglas pouch resectionDOD post operationChenevert et al., 2009 \[[@CR17]\]53I21Mucinous adenoCa & dermoid cystNoneN/ATAH/BSO/OM/PLN + CDDP/etoposideDOD 7 monthsOshita et al., 2011 \[[@CR18]\]80IIC7Endometrioid adenoCaLeft tube, parametriumRupturedTAH/BSO/PLN/OM /AP + PTX + CBDCANED 40 months65IC11Endometrioid adenoCa with squamous differentiationNoneRupturedTAH/BSO/OM + PTX/CBDCADOD 2 monthsLee et al., 2012 \[[@CR19]\]40IA30Mucinous CaNoneN/ATAH/BSO/RPLN/OM/AP + PTX/CBDCANED 8 monthsKi et al., 2014 \[[@CR20]\]58IAN/APure LCNECNoneN/ATAH/BSO/OM/PLN + PTX/CDDPDOD 17 months67IIB13Pure LCNECPelvic peritoneumN/ATAH/BSO/RPLN/OM + PTX/CBDCANED 5 monthsAsada et al., 2014 \[[@CR21]\]50IA15Mucinous adenomaNoneN/ATAH/BSO/PLN/OM + etoposide/CDDPDOD 7 monthsDing et al., 2014 \[[@CR22]\]70IA16Borderline mucinous tumorNoneN/ATAH/BSO/PLN/OM/APNED 6 monthsSehouli et al., 2016 \[[@CR23]\]23IIN/AN/AN/AN/ATAH/BSO/RPLN/OM/AP/colon resection + PTX/CBDCANED 111 months61IN/AN/AN/AN/ATAH/BSONED 37 monthsDoganay et al., 2019 \[[@CR24]\]73II10Pure LCNECUterus, bladder, rectumPositive (malignant cells)TAH/BSO/pelvic mass resection + etoposide/CDDPAEW 6 months Table 2Literature review of LCNEC of FIGO stage III and IVStudyAge (y)FIGO stageSize (cm)Associated componentMetastatic siteAscitic fluid cytologyTreatmentOutcomeEichhorn et al., 1996 \[[@CR7]\]58IIIB30Mucinous borderline tumor with small foci of mucinous adenoCaAppendix, peritoneumN/ATAH/BSO/OM/AP/LN & peritoneal biopsies + ChemDOD 8 monthsChen, 2000 \[[@CR8]\]73IIIC11Microinvasive mucinous adenoCaSmall bowel serosa, retroperitoneal LNN/ABSO/OM/RPLN+ PTX/CDDPDOD 8 monthsChoi et al., 2007 \[[@CR25]\]71IIIB6.5Serous CaRetroperitoneumN/ATAH/BSO + PTX/CBDCANED 8 monthsVeras et al., 2007 \[[@CR14]\]39IV26Mucinous adenoCaN/AN/ATAH/BSO + platinum-based ChemAWD 8 months42IVN/ABenign cyst & dermoid cyst in contralateral OVN/AN/ATAH/BSO + platinum-based ChemDOD 20 months53III14.5Endometrioid adenoCaN/AN/ATAH/BSO + platinum-based ChemNED 37 months47III14AdenoCa, not otherwise specified & mature teratomaN/AN/ATAH/BSO + platinum-based ChemNED 11 months25IV5Mature cystic teratomaN/AN/ABSO/OM/AP + platinum-based ChemDOD 36 months55III13.5Mucinous low malignant potentialN/AN/ATAH/BSO + platinum-based ChemDOD 2 months63IV14Endometrioid adenoCaN/AN/ATAH/RSO + platinum-based ChemDOD 9 monthsTsuji et al., 2008 \[[@CR26]\]46IIIC12Squamous differentiationOmentum, peritoneum, rectum, uterusN/A (bloody 2 l)subTAH/BSO/OM + PTX/CBDCADOD 4 monthsDundr et al., 2008 \[[@CR27]\]73IV9Pure LCNECMesentery, left renal capsule, CNSN/ACNS meta resection/γ Knife + TAH/BSO/OM/mesenterial meta resection/left nephrectomy + PTX/CBDCA + γ KnifeNED 12 monthsChenevert et al., 2009 \[[@CR17]\]5320IVMucinous adenoCaDouglas pouch, lungs, mediastinal LN, liver, boneN/ATAH/BSO/OM/PLN/Douglas pouch resection + PTX/CBDCADOD 3 monthsYasuoka et al., 2009 \[[@CR28]\]3626IIIA1Mucinous intraepithelial CaPeriaortic LNN/ATAH/BSO/RPLN/OM + ChemNED 6 monthsDraganova-Tacheva et al., 2009 \[[@CR29]\]68IV18Serous CaPeritoneum, omentum, uterus, bladder, colon, diaphragm, inguinal LNsPositive (papillary serous adenoCa)NAC (PTX/CBDCA) + IDS (BSO/OM) + PTX/CBDCADOD 7 monthsOshita et al., 2011 \[[@CR18]\]66IV11N/AVagina, lungsN/ANAC (PTX/CBDCA) + IDS (TAH/BSO/OM/peritoneal biopsy) + PTX/CBDCA + brain meta resection & RTNED 64 months42IIIB13Endometrioid adenoCaPeritoneumN/ATAH/BSO/RPLN/OM/Douglas pouch resection+ PTX/CBDCANED 32 monthsMiyamoto et al., 2012 \[[@CR30]\]69IV15Mature cystic teratomaPeritoneum, lungs, retroperitoneal & subclavian LNsRupturedLSO/RPLN/subclavian LN biopsies + PTX/CBDCADOD 6 monthsShakuntala et al., 2012 \[[@CR31]\]40IIIC20Pure LCNECOmentum, paraaortic LN, bowel, bladderN/A (minimal bloody)BSO/OM/PAN/bladder & sigmoid colon deposit resection + CDDP/etoposideNED 6 monthsKi et al., 2014 \[[@CR20]\]77IV15Pure LCNECSupraclavicular LNPositive (malignant cells)TAH/pelvic & neck masses resection + etoposide/CBDCADOD 45 daysCokmert et al., 2014 \[[@CR32]\]68IV20AdenoCaUterus, bladder, sigmoid colon, omentum, lungs mediastinum LN, bonesN/ATAH/BSO/RPLN/OM + RTDOD 7 monthsLin et al., 2014 \[[@CR33]\]50IV25Pure LCNECLiver, pelvic wall, intestine, left tube, parametrium, omentum, appendixN/ATAH/BSO/OM + PTX/CBDCADOD 3 monthsAgarwal et al., 2016 \[[@CR34]\]35IIIC6Pure LCNECCervix, retroperitoneal LNNegativeTAH + BSOAWD 3 monthsHerold et al., 2018 \[[@CR35]\]75IV13Pure LCNECPelvic peritoneum, retroperitoneal LN, liverN/ALaparoscopy → BSO/RPLN/OM/pelvic peritoneum & liver resection + etoposide/CBDCA + PTX/CBDCANED 36 monthsPresent31IIIC10Pure LCNECPeritoneum, omentumNegative (bloody 7 l)Diagnostic laparoscopy + etoposide/CDDPDOD 3 months*LCNEC* large cell neuroendocrine carcinoma, *Ca* carcinoma, *FIGO* International Federation of Gynecology and Obstetrics, *TAH* total abdominal hysterectomy, *BSO* bilateral salpingo-oophorectomy, *RSO* right salpingo-oophorectomy, *LSO* left salpingo-oophorectomy, *RPLN* retroperitoneal lymphadenectomy, *PLN* pelvic lymphadenectomy, *PAN* para-aortic lymphadenectomy, *OM* omentectomy, *AP* appendectomy, *IDS* interval debulking surgery, *OV* ovary, *LN* lymph node, *CNS* central nervous system, *meta* metastasis, *RT* radiation, *Chem* chemotherapy, *CDDP* cisplatin, *CPA* cyclophosphamide, *CBDCA* carboplatin, *PTX* paclitaxel, *ADR* adriamycin, *CPT-11* irinotecan, *NAC* neoadjuvant chemotherapy, *ip* intraperitoneal, *DOD* dead of disease, *NED*: no evidence of disease, *AWD* alive with disease, *N/A* no information available Fig. 3Kaplan-Meier survival curves for overall survival of LCNEC patients. The total 5-year survival is 34.6%, and median survival time is 17 months in all LCNEC patients (*n* = 53) (**a**). There are no significant differences between the cases with FIGO stage I/II (*n* = 28) and III/IV (*n* = 25), with total 5-year survival of 38.8 and 29.2% and median survival time of 19 and 9 months, respectively (*p* = 0.458) (**b**). The cases with carcinomatous peritonitis (*n* = 11) show significantly much worse clinical outcomes than cases without carcinomatous peritonitis (*n* = 42), with median survival time of 20 and 7 months, respectively (*p* = 0.036) (**c**)

In advanced epithelial ovarian cancer patients with cancerous peritonitis and ascites, ascitic fluid cytology by abdominal paracentesis before surgery can be helpful and less invasive to confirm malignant cells in the ascitic fluid to proceed to neoadjuvant chemotherapy followed by interval debulking surgery with improvement of the prognosis \[[@CR36]\]. In the present case, the patient was strongly suspected of having advanced ovarian cancer because of the huge pelvic mass, massive ascites, and their appearance on medical imaging. However, cytological examinations from ascitic fluid by abdominal paracentesis did not show any malignant cells. The previous study had shown that 96.7% of patients with carcinomatous peritonitis had positive ascitic fluid cytology \[[@CR37]\]. In our review, only 2 of 5 cases with stage I/II and 2 of 4 cases with stage III/IV had positive ascitic fluid cytology. Only in 2 cases with carcinomatous peritonitis, including the present case, ascitic fluid cytology has been reported. The present case did not show any malignant cells in the ascitic fluid, whereas another one showed malignant cells consistent with papillary serous adenocarcinoma, which was the associated component in this case \[[@CR29]\]. A previous study showed that the adenocarcinoma components were predominately located at the surface of the tumors, and most stromal and vascular invasion and lymph node metastases involved neuroendocrine components in the mixed adenoneuroendocrine carcinomas of hepatobiliary organs \[[@CR38]\], suggesting that it might be difficult to identify malignant cells derived from pure LCNEC in ascitic fluid. Therefore, pathological examination has to be performed to differentiate non-epithelial ovarian cancer or other diseases including inflammation in these LCNEC cases. In the previous cases with stage III/IV \[[@CR7], [@CR8], [@CR14], [@CR17], [@CR18], [@CR20], [@CR25]--[@CR34]\], most patients underwent laparotomy for diagnosis and treatment. However, complete surgery could not be performed in many cases, leading to the deterioration of the patients' general condition and much poorer outcomes. Therefore, a non-invasive method for differential diagnosis is needed.

The role of diagnostic laparoscopy to determine the possibility of primary optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer has been reported. In a randomized, controlled trial involving patients with suspected advanced ovarian cancer, diagnostic laparoscopy was reported to reduce the number of futile laparotomies and be reasonable to proceed with primary cytoreductive surgery if cytoreduction to less than 1 cm of residual disease seems feasible \[[@CR39]\]. Moreover, the same group has reported that diagnostic laparoscopy did not increase total direct medical health care costs or adversely affect complications or quality of life \[[@CR40]\], suggesting that laparoscopy might be a potential diagnostic procedure in advanced epithelial ovarian cancer, although port-site metastasis occurs in 16--47% of cases, and the prognostic impact is still controversial \[[@CR41]\].

In the previous cases with LCNEC, Herold et al. reported that diagnostic laparoscopy can be useful to achieve complete primary debulking surgery leading to better outcomes \[[@CR35]\]. Oshita et al. reported the usefulness of neoadjuvant chemotherapy, leading to complete interval debulking surgery and long survival \[[@CR18]\]. In the present case, the patient underwent diagnostic laparoscopy, and it was decided that the optimal surgery could not be performed because of the countless peritoneal lesions. Therefore, tissue sampling was performed without any intraoperative complications. The patient also had no postoperative complications, leading to the early start of postoperative chemotherapy. In terms of the chemotherapeutic regimen, the regimen against the epithelial component including paclitaxel and carboplatin could be considered in cases of mixed epithelial and LCNEC ovarian tumors, whereas the regimen against the neuroendocrine component including platinum-etoposide could be considered in cases of pure LCNEC \[[@CR3], [@CR42]\]. Therefore, the patient received the chemotherapy with etoposide and cisplatin, although postoperative chemotherapy did not improve the clinical outcome in the present case with carcinomatous peritonitis. Previous reports have shown the possible efficacy of paclitaxel and carboplatin, which can be less toxic than cisplatin in cases of even pure LCNEC of the ovary \[[@CR9], [@CR15], [@CR20], [@CR27], [@CR33], [@CR35]\], as well as in cases of NEC of the uterine cervix \[[@CR43]\], suggesting that these chemotherapeutic regimens could be considered in patients with poor performance status and prognosis because of unresectable carcinomatous peritonitis. Taken together, in LCNEC, diagnostic laparoscopy followed by primary debulking surgery or neoadjuvant chemotherapy might be useful in cases without carcinomatous peritonitis, whereas it might also be useful for deciding whether patients should receive less invasive chemotherapy or best supportive care in cases with carcinomatous peritonitis with much poorer outcomes.

In summary, diagnostic laparoscopy could facilitate determination of subsequent treatment, including primary debulking surgery or neoadjuvant chemotherapy, in LCNEC patients. Moreover, it can also be useful for deciding whether to give adjuvant treatment or best supportive care to LCNEC patients with carcinomatous peritonitis who show much worse clinical outcomes.
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